Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
Launched by INSIGHTEC · May 18, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Post-Exablate Pregnancy Outcomes Registry Study is looking at how women who have been treated for symptomatic uterine fibroids with a special device called Exablate are doing when it comes to pregnancy. The study aims to gather information about pregnancy outcomes and the background of fibroid treatments after women have received the Exablate treatment. This trial is currently recruiting participants who are female, and are between the ages of 18 to 62, and who have given their consent to be part of the study after their treatment.
If you decide to join this study, you'll help researchers understand more about how Exablate treatment affects women's chances of becoming pregnant afterward. Participants will provide information about their experiences and outcomes after the treatment. This study is important because it will help improve care for women facing similar issues in the future.
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria: - - Eligibility is as per the symptomatic fibroids device indication. - All registry-consented patients following the treatment of their fibroid(s) with the Exablate system. Exclusion Criteria: -
About Insightec
Insightec is a pioneering medical technology company specializing in non-invasive therapeutic ultrasound solutions. With a focus on advancing patient care, Insightec develops innovative treatments for neurological and other medical conditions using its proprietary Exablate platform, which integrates MRI-guided focused ultrasound. The company is committed to conducting rigorous clinical trials to validate the safety and efficacy of its therapies, aiming to transform the landscape of traditional surgical interventions and improve outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Stanford, California, United States
Los Angeles, California, United States
Shanghai, , China
Shanghai, Hongkou District, China
Shanghai, , China
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials